Last updated: February 25, 2026
What is the excipient profile of INFUVITE ADULT?
INFUVITE ADULT is a multivitamin intravenous (IV) formulation containing essential vitamins and minerals. Its excipient composition is tailored to ensure stability, bioavailability, and compatibility with intravenous delivery. The product typically includes:
-
Active ingredients: Thiamine (Vitamin B1), Riboflavin (Vitamin B2), Niacinamide (Vitamin B3), Pyridoxine (Vitamin B6), Cyanocobalamin (Vitamin B12), Folic acid, and minerals like Zinc and Copper.
-
Excipients: The formulation uses a combination of stabilizers, buffers, solvents, and preservatives.
Common excipients include:
- Sodium phosphate buffer: Maintains pH stability (around 4.5–5.5).
- Sodium chloride: Isotonicity adjustment.
- Water for injection: Solvent.
- Preservatives (in some formulations): Methylparaben or other minor preservatives for multi-dose vials.
The excipient selection prioritizes stability and minimizes interactions that could compromise vitamin integrity or cause incompatibility issues during infusion.
How does excipient strategy influence formulation stability and safety?
Excipient choice in INFUVITE ADULT serves several roles:
- pH stabilization: Maintains vitamin stability without causing precipitation or degradation.
- Isotonicity: Ensures patient comfort and reduces venous irritation.
- Compatibility: Prevents precipitation and chemical interactions—particularly important for vitamins susceptible to oxidation or hydrolysis.
- Preservation: Extends shelf life, especially in multi-dose vials.
The buffer system and antioxidants used directly impact shelf life, sterility, and patient safety. A stable excipient framework reduces the risk of infusion reactions and ensures consistent dosing.
What commercial opportunities exist through excipient innovation?
Innovative excipient strategies can expand market potential:
1. Enhanced Stability and Shelf Life
Developing novel stabilizers or antioxidants can:
- Extend shelf life beyond current limits.
- Improve storage conditions, enabling distribution to warmer or remote regions.
- Reduce need for cold chain logistics.
2. Formulation of Ready-to-Use (RTU) Solutions
Innovations in excipients can enable pre-mixed, ready-to-use formulations:
- Minimizes preparation errors.
- Reduces contamination risk.
- Facilitates hospital and emergency room adoption.
3. Compatibility with Combination Therapies
Tailoring excipients to allow co-administration with other IV drugs:
- Increases versatility.
- Facilitates combination regimens for complex patient needs like critical care.
4. Reduced Infusion Reactions
Incorporating excipients that mitigate infusion-related adverse events:
- Improved tolerability can expand patient populations.
- Potential for premium pricing.
5. Patient-Centric Formulation Features
Using biocompatible excipients that lower osmolality or reduce phlebitis.
- Enhances patient comfort.
- Supports outpatient and home infusion services.
6. Regulatory Differentiation
Using excipients with documented safety profiles can streamline approval:
- Leverages existing regulatory approvals.
- Shortens time-to-market.
What are key regulatory considerations?
Regulatory agencies like the FDA and EMA emphasize excipient safety and consistency. For INFUVITE ADULT:
- Documentation: Excipient sources and batch consistency are critical.
- Labeling: Clear identification of excipients, especially preservatives or stabilizers.
- Stability Data: Must demonstrate excipient compatibility and impact on drug stability.
- Compliance with pharmacopoeias: US Pharmacopeia (USP), European Pharmacopoeia (EP) standards.
Aligning excipient choices with regulatory standards is essential for market expansion and avoiding delays.
What are competitive differentiators in excipient strategy?
Competitive advantages stem from:
- Use of novel, efficient stabilizers increasing shelf stability.
- Reduced excipient load for better tolerability.
- Incorporation of excipients that enable novel delivery modes or formulations.
- Proven safety profiles aligning with regulatory expectations.
Investing in excipient R&D can position INFUVITE ADULT as a superior option in the IV multivitamin market.
Summary table: Excipient characteristics and commercial implications
| Aspect |
Details |
Commercial impact |
| pH buffers |
Sodium phosphate, citrate buffers |
Ensures stability, shelf life |
| Solvents |
Water for injection |
Compatibility with IV delivery |
| Stabilizers |
Antioxidants like EDTA or sodium metabisulfite (if applicable) |
Prevent oxidation, extend shelf life |
| Isotonic agents |
Sodium chloride, dextrose (if used) |
Patient safety, comfort |
| Preservatives (multi-dose) |
Methylparaben, propylparaben (if needed) |
Longer shelf life |
Key Takeaways
- Excipients in INFUVITE ADULT primarily include buffers, stabilizers, and isotonic agents optimized for stability and safety.
- Innovation in excipient chemistry can extend shelf life, improve safety, and enable new formulations.
- Compatibility with combination therapies and tolerability enhancements offer market expansion opportunities.
- Regulatory compliance relies heavily on excipient safety profiles and quality control.
- Differentiation hinges on using excipients that support stability, safety, and convenience.
FAQs
1. Can excipient modifications improve INFUVITE ADULT’s shelf life?
Yes. Using advanced stabilizers and antioxidants can slow degradation, extending shelf life.
2. Are there opportunities to reduce excipient load for better tolerability?
Yes. Smaller excipient quantities or biocompatible excipients can reduce infusion reactions.
3. How does excipient choice affect regulatory approval?
Regulatory agencies scrutinize excipient safety, source, and stability data. Familiar, well-documented excipients expedite approval.
4. What excipient innovations could enable at-home infusion use?
Enhanced stability, ready-to-use formulations, and minimal infusion-related reactions support outpatient settings.
5. Is there potential to develop multi-drug IV formulations involving INFUVITE?
Yes. Compatibility-focused excipient strategies facilitate co-administration with other IV therapies, broadening therapeutic options.
References
[1] U.S. Food and Drug Administration. (2021). Guidance for Industry: Nonclinical Studies for the Safety of Human Drugs and Biological Products.
[2] European Medicines Agency. (2019). Guideline on excipients in the dossier for application for marketing authorization of a medicinal product.
[3] Lefebvre, B., et al. (2020). Advances in IV multivitamin formulations: stabilizer strategies. Journal of Parenteral and Enteral Nutrition, 44(3), 390-399.
[4] World Health Organization. (2010). Quality Assurance of Pharmaceuticals: A compendium of guidelines and related materials.
